Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Notes Payables (2023 - 2026)

Lucid Diagnostics filings provide 3 years of Notes Payables readings, the most recent being $24.0 million for Q4 2025.

  • On a quarterly basis, Notes Payables rose 29.03% to $24.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.0 million, a 29.03% increase, with the full-year FY2025 number at $24.0 million, up 29.03% from a year prior.
  • Notes Payables hit $24.0 million in Q4 2025 for Lucid Diagnostics, up from $22.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $32.8 million in Q1 2025 to a low of $10.2 million in Q3 2024.
  • Median Notes Payables over the past 3 years was $14.2 million (2023), compared with a mean of $17.5 million.
  • Biggest five-year swings in Notes Payables: decreased 29.61% in 2024 and later soared 150.38% in 2025.
  • Lucid Diagnostics' Notes Payables stood at $14.0 million in 2023, then soared by 33.33% to $18.6 million in 2024, then increased by 29.03% to $24.0 million in 2025.
  • The last three reported values for Notes Payables were $24.0 million (Q4 2025), $22.3 million (Q3 2025), and $25.3 million (Q2 2025) per Business Quant data.